Endoscopic duodenal mucosal resurfacing for treating obesity and metabolic diseases: State-of-the-art review

키워드

참고문헌 (27)

1. Cho N, "IDF Diabetes Atlas : Global estimates of diabetes prevalence for 2017 and projections for 2045", Diabetes Res Clin Pract, 138, pp.271~281 (2018)
2. "Understanding Adult Overweight & Obesity"[URL]
3. Resnick HE, "Achievement of American Diabetes Association clinical practice recommendations among U. S. adults with diabetes, 1999-2002 : the National Health and Nutrition Examination Survey", Diabetes Care, 29, pp.531~537 (2006)
4. Jackness C, "Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and β-cell Function in type 2 diabetic patients", Diabetes, 62, pp.3027~3032 (2013)
5. Biertho L, "Laparoscopic sleeve gastrectomy: with or without duodenal switch? A consecutive series of 800 cases", Dig Surg, 31, pp.48~54 (2014)
6. Rubino F, "The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes", Ann Surg, 244, pp.741~749 (2006)
7. Zervos EE, "Amelioration of insulin requirement in patients undergoing duodenal bypass for reasons other than obesity implicates foregut factors in the pathophysiology of type II diabetes", J Am Coll Surg, 210, pp.564~572 (2010)
8. Theodorakis MJ, "Human duodenal enteroendocrine cells : source of both incretin peptides, GLP-1and GIP", Am J Physiol Endocrinol Metab, 290, pp.E550~E559 (2006)
9. Nguyen NQ, "Accelerated intestinal glucose absorption in morbidly obese humans : relationship to glucose transporters, incretin hormones, and glycemia", J Clin Endocrinol Metab, 100, pp.968~976 (2015)
10. Gniuli D, "Highfat feeding stimulates endocrine, glucose-dependent insulinotropic polypeptide(GIP)-expressing cell hyperplasia in the duodenum of Wistar rats", Diabetologia, 53, pp.2233~2240 (2010)
11. Salinari S, "Nutrient infusion bypassing duodenum-jejunum improves insulin sensitivity in glucose-tolerant and diabetic obese subjects", Am J Physiol Endocrinol Metab, 305, pp.E59~E66 (2013)
12. Habegger KM, "Duodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia", Gut, 63, pp.1238~1246 (2014)
13. Klein S, "Moderate effect of duodenal-jejunal bypass surgery on glucose homeostasis in patients with type 2 diabetes", Obesity(Silver Spring), 20, pp.1266~1272 (2012)
14. Machytka E, "Partial jejunal diversion using an incisionless magnetic anastomosis system : 1-year interim results in patients with obesity and diabetes", Gastrointest Endosc, 86, pp.904~912 (2017)
15. Peter S, "Ablative endoscopic therapies for Barrett's-esophagusrelated neoplasia", Gastroenterol Clin North Am, 44, pp.337~353 (2015)
16. Haidry RJ, "Duodenal mucosal resurfacing : proof-of-concept, procedural development, and initial implementation in the clinical setting", Gastrointest Endosc, 90, pp.673~681. e2 (2019)
17. Rajagopalan H, "Endoscopic duodenal mucosal resurfacing for the treatment of type 2diabetes : 6-month interim analysis from the first-in-human proof-of-concept study", Diabetes Care, 39, pp.2254~2261 (2016)
18. Hadefi A, "Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes", Dig Dis, 36, pp.322~324 (2018)
19. van Baar ACG, "Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus : one year results from the first international, open-label, prospective, multicentre study", Gut, 69, pp.295~303 (2020)
20. van Baar ACG, "Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes : a feasibility study", Gastrointest Endosc, 94, pp.111~120.e3 (2021)
21. Mingrone G, "Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes : the randomised, double-blind, sham-controlled, multicentre REVITA-2feasibility trial", Gut, 71, pp.254~264 (2022)
22. van Baar ACG, "Durable metabolic improvements 2 years after duodenal mucosal resurfacing(DMR)in patients with type 2 diabetes(REVITA-1 Study)", Diabetes Res Clin Pract, 184, pp.109194~ (2022)
23. Kaur V, "Mechanisms of action of duodenal mucosal resurfacing in insulin resistant women with polycystic ovary syndrome", Metabolism, 125, pp.154908~ (2021)
24. de Oliveira GHP, "Metabolic effects of endoscopic duodenal mucosal resurfacing : a systematic review and meta-analysis", Obes Surg, 31, pp.1304~1312 (2021)
25. Hasan NM, "Intestinal stem cell-derived enteroids from morbidly obese patients preserve obesityrelated phenotypes : elevated glucose absorption and gluconeogenesis", Mol Metab, 44, pp.101129~ (2021)
26. Yang H, "Potential therapeutic mechanism of duodenal mucosal resurfacing", Gastrointest Endosc, 94, pp.1015~1016 (2021)
27. Meiring S, "Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2diabetes", Am J Physiol Endocrinol Metab, 322, pp.E132~E140 (2022)

관련 논문AI추천